Sponsored by
Cancer Res. 2009 Dec 15;69(24):9157-9.
Mutant metabolic enzymes are at the origin of gliomas.
Yan H, Bigner DD, Velculescu V, Parsons DW.
The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina, USA. hai.yan@duke.edu
Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within the isocitrate binding site (R132 of IDH1 and the analogous R172 residue of IDH2). IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.
PMID: 19996293 [PubMed - indexed for MEDLINE]